Clinical Trial Update: Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas [Phase 2]

View source ↗

Summary

This clinical trial update notes that the Phase 2 study of the anti-CD20 antibody ofatumumab in older patients with untreated indolent B-cell lymphomas has been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Indolent Non-hodgkin Lymphoma
• Marginal Zone B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Arzerra (ofatumumab)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Follicular | Phase 2 | Status: WITHDRAWN